COVID-19 CORONAVIRUS-SARS-CoV-2 U07.1
Conditions
Interventions
Group 1: In 100, randomly selected constituencies out of 755, 3,000 Munich households are identified via random route and offered enrolment into the study.
All household members are asked to complete
Sponsors
Abteilung für Infektions- und Tropenmedizin,LMU Klinikum
Eligibility
Sex/Gender
All
Age
2 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria are: • At the time of inclusion into the study (1st household visit), at least one of the household members must be =18 years and competent to provide written informed consent. • Sufficient command of German to understand the participant information materials for the study and to answer the questionnaires.
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sero-prevalence and -incidence of SARS-CoV-2 antibodies in a representative household sample of the Munich population | — |
Secondary
| Measure | Time frame |
|---|---|
| Baseline visit: • What is the SARS-CoV-2 antibody prevalence in the Munich general population? First study round april-july 2020; and second study round november 2020-january 2021, third study round starting on march 2021 • How many of the initially seropositive individuals in the baseline-study were previously tested by pharyngeal swab and nucleic acid amplification (PCR) (positively or negatively) and/or had symptoms suggestive for COVID-19 (yes or no)? • What is the distribution of symptom severity in each of the groups described above? • How high is the risk of infection for other household members if one person is infected and can household risk factors be identified? • How high is the risk of infection for other inhabitants of the same apartment or building if one person is infected? • What are the risk factors for SARS-CoV-2 infections? Follow-up visits: • Is there a change in antibody titers of those who initially tested positive, which is potentially necessary to discriminate from cross-reactivity with other corona viruses? • How long are SARS-CoV-2 specific antibodies detectable after infections of varying severity? • How does the spread of the disease develop and what influence do public health measures have on the incidence? • What is the impact of individual behaviour on the incidence of infection? • Which risk factors are associated with SARS-CoV-2 incidence? • What is the socio-economic impact of the pandemic and the measures to combat it, especially on the employment situation and psychosocial endpoints? | — |
Countries
Germany
Contacts
Public ContactMichael Pritsch
Abteilung für Infektions- und Tropenmedizin,LMU Klinikum
Outcome results
None listed